CRISPR Therapeutics AG
COMPOSITIONS AND METHODS FOR GENE EDITING
Last updated:
Abstract:
The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.
Status:
Application
Type:
Utility
Filling date:
21 Feb 2018
Issue date:
21 May 2020